Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04001517
Previous Study | Return to List | Next Study

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (AscenD-LB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04001517
Recruitment Status : Recruiting
First Posted : June 28, 2019
Last Update Posted : October 24, 2019
Sponsor:
Collaborator:
Worldwide Clinical Trials
Information provided by (Responsible Party):
EIP Pharma Inc

Brief Summary:
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, proof-of-principle study of neflamapimod versus matching placebo (randomized 1:1) administered with food for 16 weeks in subjects with DLB. The primary objective is to evaluate the effect of neflamapimod on cognitive function as assessed in a study-specific Cogstate Neuropsychological Test Battery (NTB). Secondary endpoints include the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI-10), Timed Up and Go Test, and electroencephalogram (EEG) as a potential biomarker for DLB.

Condition or disease Intervention/treatment Phase
Dementia With Lewy Bodies (DLB) Drug: Neflamapimod Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)
Actual Study Start Date : September 30, 2019
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Neflamapimod
40 mg capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing <80 kg or the TID regimen if weighing ≥80 kg
Drug: Neflamapimod
Double-Blind, Placebo-Controlled

Placebo Comparator: Placebo
40 mg matching placebo capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing <80 kg or the TID regimen if weighing ≥80 kg
Drug: Neflamapimod
Double-Blind, Placebo-Controlled




Primary Outcome Measures :
  1. Composite score of a study-specific Cogstate Neurological Test Battery (NTB) including the Cogstate Letter Fluency Test and Category Fluency Test [ Time Frame: 16 weeks ]
    Change from Baseline to Week 16 in the composite score of a study-specific Cog-state Neurological Test Battery (NTB), including assessments of attention, executive function, and visuospatial function in neflamapimod treated-subjects as compared to the placebo-treated subjects, as analyzed using the Mixed Model Repeated Measures (MMRM) analysis method. The following six tests will be included in the composite: (1) Cogstate Detection test (DET), (2) Cogstate Identification test (IDN), (3) Cogstate One Card Learning test (OCL), (4) Cogstate One Back test (ONB), (5) Letter Fluency Test, (6) Category Fluency Test (CFT). Each score on the individual tests will be converted to a z-score, and then a total z-score will be calculated, in which each test is weighted equally. The change in total z-score in neflamapimod vs. placebo-recipients will be analyzed. As the analysis is based on z-scores, there is no minimum or maximum value.


Secondary Outcome Measures :
  1. Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) [ Time Frame: 16 weeks ]
    Change in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) score based on semi-quantitative scoring of each domain (box) evaluating cognitive impairment in milder and more progressive forms of dementia, in neflamapimod-treated subjects compared to placebo-recipients. The domain (box) scores will be calculated for a Sum of Boxes score. Secondary efficacy endpoints will utilize the same analysis method and model as the primary endpoint.

  2. Mini-Mental State Examination (MMSE) [ Time Frame: 16 weeks ]
    Change in Mini-Mental State Examination (MMSE) with respect to orientation, memory, concentration, language, and praxis (scores ranging from 0 to 30 with lower scores indicating greater cognitive impairment), in neflamapimod-treated subjects compared to placebo-recipients. Secondary efficacy endpoints will utilize the same analysis method and model as the primary endpoint.

  3. Neuropsychiatric Inventory (NPI-10) [ Time Frame: 16 weeks ]
    Change in Neuropsychiatric Inventory (NPI-10) domains, specifically depression (dysphoria), anxiety, hallucinations, and agitation/aggression, in neflamapimod-treated subjects compared to placebo-recipients. Responses indicating subject has a problem with a particular sub-domain lead to questions of the caregiver rating the frequency of the symptoms on a 4-point scale, severity on a 3-point scale, and the distress the symptoms cause them on a 5-point scale. Secondary efficacy endpoints will utilize the same analysis method and model as the primary endpoint.

  4. International Shopping List Test (ISLT) [ Time Frame: 16 weeks ]
    Change in International Shopping List Test (ISLT) immediate and delayed recall and recognition will be used to assess episodic memory in neflamapimod-treated subjects compared to placebo-recipients. Secondary efficacy endpoints will utilize the same analysis method as the primary endpoint.

  5. Timed Up and Go Test (TUG) [ Time Frame: 16 weeks ]
    Change in Timed Up and Go Test (TUG) to assess mobility (score of >15 seconds indicates subject has increased risk of falls) in neflamapimod-treated subjects compared to placebo-recipients. Secondary efficacy endpoints will utilize the same analysis method and model as the primary endpoint.

  6. Quantitative Electroencephalogram (qEEG) [ Time Frame: 16 weeks ]
    Change in quantitative electroencephalogram (qEEG) parameters (all waveforms, with particular focus on relative alpha and theta power) with the subject awake in accordance with the 10-20 International System of Electrode placement will be evaluated as a potential biomarker for DLB. Slowing of the dominant frequency band by qEEG over posterior aspects of the brain has been recognized to be prominent in DLB, and various patterns have been identified to differentiate DLB from AD. EEG will be analyzed at an academic center (VU Medical Center, Amsterdam), who will develop the specific parameters during the conduct of the study, and they will specify the analytic approach in the Statistical Analysis Plan (SAP) that will be implemented prior to the completion of subject enrollment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men and women aged ≥55 years.
  2. Subject or subject's legally authorized representative is willing and able to provide written informed consent.
  3. Probable DLB and identified cognitive deficits, according to current consensus criteria (McKeith et al, 2017), specifically one core clinical feature and a positive DaTscan. If a negative DaTscan, but the subject has historical PSG-verified RBD, the subject would also qualify.
  4. MMSE score of 15-28, inclusive, during Screening.
  5. Currently receiving cholinesterase inhibitor therapy, having received such therapy for greater than 3 months and on a stable dose for at least 6 weeks at the time of randomization. Except for reducing the dose for tolerability reasons, the dose of cholinesterase inhibitor may not be modified during the study.
  6. Normal or corrected eye sight and auditory abilities, sufficient to perform all aspects of the cognitive and functional assessments.
  7. No history of learning difficulties that may interfere with their ability to complete the cognitive tests.
  8. Must have reliable informant or caregiver.

Exclusion Criteria:

  1. Diagnosis of any other ongoing central nervous system (CNS) condition other than DLB, including, but not limited to, post-stroke dementia, vascular dementia, Alzheimer's disease (AD), or Parkinson's disease (PD).
  2. Suicidality, defined as active suicidal thoughts within 6 months before Screening or at Baseline, defined as answering yes to items 4 or 5 on the C-SSRS, or history of suicide attempt in previous 2 years, or, in the Investigator's opinion, at serious risk of suicide.
  3. Ongoing major and active psychiatric disorder and/or other concurrent medical condition that, in the opinion of the Investigator, might compromise safety and/or compliance with study requirements.
  4. Diagnosis of alcohol or drug abuse within the previous 2 years.
  5. Poorly controlled clinically significant medical illness, such as hypertension (blood pressure >180 mmHg systolic or 100 mmHg diastolic); myocardial infarction within 6 months; uncompensated congestive heart failure or other significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would interfere with assessment of drug safety.
  6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 × the upper limit of normal (ULN), total bilirubin >1.5 × ULN, and/or International Normalized Ratio (INR) >1.5.
  7. Known human immunodeficiency virus, hepatitis B, or active hepatitis C virus infection.
  8. Participated in a study of an investigational drug less than 3 months or 5 half-lives of an investigational drug, whichever is longer, before enrollment in this study.
  9. History of previous neurosurgery to the brain.
  10. If male with female partner(s) of child-bearing potential, unwilling or unable to adhere to contraception requirements specified in the protocol.
  11. If female who has not has not reached menopause >1 year previously or has not had a hysterectomy or bilateral oophorectomy/salpingo-oophorectomy, has a positive pregnancy test result during Screening and/or is unwilling or unable to adhere to the contraception requirements specified in the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04001517


Contacts
Layout table for location contacts
Contact: John Alam, MD 617-863-3751 jalam@eippharma.com

Locations
Layout table for location information
United States, California
Pacific Neuroscience Institute Recruiting
Santa Monica, California, United States, 90404
Contact: Mini Gill       jaya.gill@providence.org   
Principal Investigator: Santosh Kesari, MD         
United States, Colorado
University of Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Abigail Simpson       abigail.simpson@cuanschutz.edu   
Principal Investigator: Samantha Holden, MD         
United States, Florida
Elite Clinical Research Recruiting
Miami, Florida, United States, 33144
Contact: Nuvia Herrera       nuvia.elite@live.com   
Principal Investigator: Gelasio Baras, MD         
United States, Kansas
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66103
Contact: Emily Gamel       egamel@kumc.edu   
Principal Investigator: Rajesh Pahwa, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Charlestown, Massachusetts, United States, 02129
Contact: Brooke Fortin       bfortin@mgh.harvard.edu   
Principal Investigator: Stephen Gomperts, MD         
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48105
Contact: Jackie Dobson       jdobson@med.umich.edu   
Principal Investigator: Nicolaas Bohnen, MD         
United States, Nevada
Cleveland Clinic - Lou Ruvo Center for Brain Health Recruiting
Las Vegas, Nevada, United States, 89106
Contact: Heather Hudson       hudsonh@ccf.org   
Principal Investigator: Aaron Ritter, MD         
United States, New York
University of Rochester Recruiting
Rochester, New York, United States, 14618
Contact: Nicole Guerrero       nicole_guerrero@URMC.Rochester.edu   
Principal Investigator: Katherine Amodeo, MD         
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Contact: Christine Whitman       whitmac@ccf.org   
Principal Investigator: Babak Tousi, MD         
The Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact: Brooke Eiginger       brooke.eiginger@osumc.edu   
Principal Investigator: Douglas Scharre, MD         
United States, Oregon
Summit Research Network Recruiting
Portland, Oregon, United States, 97210
Contact: Fernanda Coletti       fcoletti@summitnetwork.com   
Principal Investigator: Scott Losk, PhD         
Oregon Health & Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Audrey Anderson       anderaud@ohsu.edu   
Principal Investigator: Joseph Quinn, MD         
United States, Pennsylvania
Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Aaron Roberts       aaron.roberts@jefferson.edu   
Principal Investigator: Carol Lippa, MD         
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Colleen Webber       cmn6x@virginia.edu   
Principal Investigator: Matthew Barrett, MD         
National Clinical Research, Inc. Recruiting
Richmond, Virginia, United States, 23294
Contact: Kelly Gilpatrick       kgilpatrick@ncrinc.net   
Principal Investigator: John Scott, MD         
United States, Washington
Northwest Clinical Research Center Recruiting
Bellevue, Washington, United States, 98007
Contact: Leslie Gills       lgills@nwcrc.net   
Principal Investigator: Arifulla Khan, MD         
University of Washington Recruiting
Seattle, Washington, United States, 98104
Contact: Yeung Tutterrow       ylt2@uw.edu   
Principal Investigator: Charles Bernick, MD         
Inland Northwest Research Recruiting
Spokane, Washington, United States, 99202
Contact: Deann Dickinson       ddickinson@inwresearch.com   
Principal Investigator: Steven Pugh, MD         
Sponsors and Collaborators
EIP Pharma Inc
Worldwide Clinical Trials
Investigators
Layout table for investigator information
Study Director: John Alam, MD EIP Pharma

Layout table for additonal information
Responsible Party: EIP Pharma Inc
ClinicalTrials.gov Identifier: NCT04001517     History of Changes
Other Study ID Numbers: EIP19-NFD-501
First Posted: June 28, 2019    Key Record Dates
Last Update Posted: October 24, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dementia
Lewy Body Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Neurodegenerative Diseases
Parkinsonian Disorders
Basal Ganglia Diseases
Movement Disorders